Last reviewed · How we verify

NCT01595620

Cannabinoid Modulation of Pain

Completed EARLY_PHASE1 Last updated 9 March 2022
What this trial tests

EARLY_PHASE1 trial testing Thermal in Pain in 6 participants. Completed in 19 April 2012.

Timeline
9 November 2011
Primary endpoint
19 April 2012
19 April 2012

Quick facts

Lead sponsorYale University
PhaseEARLY_PHASE1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingquadruple
Primary purposehealth services research
Enrollment6
Start date9 November 2011
Primary completion19 April 2012
Estimated completion19 April 2012
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Yale University

Who can join

Adults 18 to 55, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the effects of cannabinoids on pain response using a variety of human experimental pain models.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Cannabinoid Formulations and Delivery Systems: Current and Future Options to Treat Pain.
    Stella B, Baratta F, Della Pepa C, Arpicco S, et al · · 2021 · cited 103× · PMID 34480749 · DOI 10.1007/s40265-021-01579-x

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Yale University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01595620.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing